Astellas installs president at OSI
This article was originally published in Scrip
Astellas has named Naoki Okamura as president of its wholly owned US subsidiary OSI Pharmaceuticals. Mr Okamura was formerly an executive in Astellas's licensing and alliances department. Around a month ago, the Japanese firm completed its $4 billion acquisition of OSI, whose CEO is Dr Colin Goddard. The move will give Astellas a greater presence in the oncology sector and the US market (scripintelligence.com, 17 May 2010).
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.